CIANCIO, Alessia
 Distribuzione geografica
Continente #
NA - Nord America 2.918
EU - Europa 2.067
AS - Asia 1.312
AF - Africa 110
SA - Sud America 59
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.517
Nazione #
US - Stati Uniti d'America 2.818
IT - Italia 624
DE - Germania 614
CN - Cina 589
FR - Francia 217
GB - Regno Unito 153
IN - India 140
JP - Giappone 125
VN - Vietnam 110
CA - Canada 79
TW - Taiwan 64
HK - Hong Kong 56
ES - Italia 49
KR - Corea 49
IE - Irlanda 48
RU - Federazione Russa 45
AU - Australia 43
NL - Olanda 40
PL - Polonia 36
EG - Egitto 26
PK - Pakistan 25
BR - Brasile 24
CZ - Repubblica Ceca 24
RO - Romania 24
GR - Grecia 23
SE - Svezia 23
SG - Singapore 23
TR - Turchia 23
ZA - Sudafrica 22
ID - Indonesia 20
AT - Austria 19
CH - Svizzera 17
CO - Colombia 17
FI - Finlandia 16
MY - Malesia 16
MX - Messico 15
UA - Ucraina 15
CL - Cile 14
NG - Nigeria 14
BG - Bulgaria 11
IQ - Iraq 11
PH - Filippine 11
PT - Portogallo 11
BE - Belgio 10
DK - Danimarca 10
TH - Thailandia 9
GH - Ghana 8
IR - Iran 8
LT - Lituania 8
ET - Etiopia 7
KE - Kenya 7
SA - Arabia Saudita 7
NZ - Nuova Zelanda 6
CM - Camerun 5
HR - Croazia 5
LY - Libia 5
MD - Moldavia 5
CR - Costa Rica 4
NO - Norvegia 4
PE - Perù 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
YE - Yemen 4
IL - Israele 3
MV - Maldive 3
UZ - Uzbekistan 3
BD - Bangladesh 2
BF - Burkina Faso 2
CI - Costa d'Avorio 2
CY - Cipro 2
KZ - Kazakistan 2
LV - Lettonia 2
SN - Senegal 2
TG - Togo 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GM - Gambi 1
GN - Guinea 1
HU - Ungheria 1
JM - Giamaica 1
MK - Macedonia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
QA - Qatar 1
SD - Sudan 1
Totale 6.517
Città #
Fairfield 325
Houston 276
Woodbridge 228
Ann Arbor 190
Santa Cruz 150
Ashburn 143
Beijing 131
Seattle 130
Buffalo 118
Torino 116
Wilmington 103
Cambridge 89
Shanghai 77
Dong Ket 51
Guangzhou 50
Nürnberg 49
Dublin 46
Wuhan 45
Rome 44
Hanoi 42
Chicago 37
San Diego 37
Taipei 37
Bengaluru 34
Pisa 33
Warsaw 32
Milan 31
University Park 29
Los Angeles 25
Mountain View 25
Tokyo 24
New York 22
Toronto 22
Chandler 21
Coutras 21
Delhi 20
Ottawa 19
Turin 19
Changchun 17
Lanzhou 17
Muizenberg 17
Cardiff 16
Phoenix 16
Singapore 16
Xian 16
Las Vegas 15
Nanjing 15
Boardman 14
Changsha 14
Central 13
Central District 13
Chengdu 13
Duncan 13
Hangzhou 13
Heidelberg 13
Redmond 13
Boulder 12
Council Bluffs 12
Lake Forest 12
Vienna 12
Clearwater 11
Kuala Lumpur 11
Palermo 11
Bologna 10
Columbus 10
Dallas 10
Jakarta 10
Des Moines 9
Helsinki 9
Mumbai 9
Accra 8
Brooklyn 8
Groningen 8
Jinan 8
Milpitas 8
Palagiano 8
Gurgaon 7
Herndon 7
Laurel 7
Manchester 7
Paris 7
Rochester 7
San Francisco 7
San Jose 7
Seoul 7
Shenyang 7
Sydney 7
Chester 6
Dearborn 6
Hartford 6
Henderson 6
Istanbul 6
Karachi 6
Lagos 6
Santiago 6
Shenzhen 6
Suzhou 6
Athens 5
Barcelona 5
Bergamo 5
Totale 3.503
Nome #
Outcome of chronic delta hepatitis in Italy: a long-term cohort study., file e27ce426-c380-2581-e053-d805fe0acbaa 652
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma, file e27ce42a-4f47-2581-e053-d805fe0acbaa 606
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis, file e27ce42e-8e39-2581-e053-d805fe0acbaa 374
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents, file e27ce42e-a4c2-2581-e053-d805fe0acbaa 358
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study, file e27ce42c-6c73-2581-e053-d805fe0acbaa 343
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α, file e27ce42b-ae29-2581-e053-d805fe0acbaa 322
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment., file e27ce426-edaf-2581-e053-d805fe0acbaa 290
DURABILITY OF THE RESPONSE TO PEGINTERFERON ALFA2b AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A COHORT STUDY IN THE ROUTINE CLINICAL SETTING., file e27ce426-fea5-2581-e053-d805fe0acbaa 279
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients., file e27ce42a-76ff-2581-e053-d805fe0acbaa 257
The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta, file e27ce42a-265e-2581-e053-d805fe0acbaa 249
Management of Pt1 tumours removed by endoscopy during colorectal cancer screening: Outcome and treatment quality indicators, file e27ce42d-404b-2581-e053-d805fe0acbaa 240
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection, file e27ce42d-2ee7-2581-e053-d805fe0acbaa 231
Hepatitis: PEG-IFN for the treatment of hepatitis D, file e27ce426-d40b-2581-e053-d805fe0acbaa 227
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II, file e27ce42f-18ea-2581-e053-d805fe0acbaa 226
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study, file e27ce42e-18f4-2581-e053-d805fe0acbaa 218
AISF position paper on liver disease and pregnancy., file e27ce429-082c-2581-e053-d805fe0acbaa 173
A Review of HDV Infection, file 45a4f9c4-447b-4a23-8372-63d95324c397 168
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients, file e27ce427-0c0c-2581-e053-d805fe0acbaa 163
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma., file e27ce42a-6ef3-2581-e053-d805fe0acbaa 163
Peripheral neuropathy after viral eradication with direct-acting antivirals in chronic HCV hepatitis: A prospective study, file e27ce432-93a4-2581-e053-d805fe0acbaa 148
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study, file e27ce42e-fdbf-2581-e053-d805fe0acbaa 126
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura, file e27ce42a-f451-2581-e053-d805fe0acbaa 107
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study, file e27ce427-0b92-2581-e053-d805fe0acbaa 100
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy, file e27ce42e-fdc1-2581-e053-d805fe0acbaa 94
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?, file e27ce42e-e7c5-2581-e053-d805fe0acbaa 85
The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease, file e27ce433-7ea9-2581-e053-d805fe0acbaa 64
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection, file e27ce42f-3175-2581-e053-d805fe0acbaa 62
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma, file e27ce432-1f74-2581-e053-d805fe0acbaa 59
Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response?, file e27ce430-46ab-2581-e053-d805fe0acbaa 50
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease, file e27ce42c-40be-2581-e053-d805fe0acbaa 49
Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study, file e27ce432-61f2-2581-e053-d805fe0acbaa 47
Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development, file 5c38c060-c792-4a26-9202-4b8155c39c61 36
Addition of Bismuth to the Standard Triple Therapy for Helicobacter Pylori Infection, file e27ce42e-e7c3-2581-e053-d805fe0acbaa 26
Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension Following Hepatitis C Virus Eradication in Cirrhotic Individuals, file 477fa16e-2564-406b-9879-3fdc31dd7ba0 25
Importance of HLA-B in the sustained virological response in patients with chronic hepatitis C treated with peg-IFN and ribavirin, file e27ce42e-ed5e-2581-e053-d805fe0acbaa 22
Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification, file e27ce435-1e84-2581-e053-d805fe0acbaa 20
Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals, file e27ce434-d885-2581-e053-d805fe0acbaa 19
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment., file e27ce426-eb1c-2581-e053-d805fe0acbaa 15
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II, file e27ce42b-da07-2581-e053-d805fe0acbaa 11
Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis, file 8556369a-91e9-4de2-9d85-3378ced85e1f 9
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study, file e27ce42b-dbfa-2581-e053-d805fe0acbaa 9
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy, file e27ce434-baaa-2581-e053-d805fe0acbaa 9
Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study, file 4d537272-496d-4109-9603-34e62429d077 6
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection, file e27ce42c-ffa8-2581-e053-d805fe0acbaa 5
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients., file e27ce42a-7700-2581-e053-d805fe0acbaa 4
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination., file 16ca2905-dabf-4aae-88b2-ae44a7181f2a 3
COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization., file d17830e9-3642-4b14-a354-c95ef39bfcaa 3
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner., file e27ce428-ca85-2581-e053-d805fe0acbaa 3
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis, file e27ce42e-92a3-2581-e053-d805fe0acbaa 3
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma, file e27ce432-6166-2581-e053-d805fe0acbaa 3
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort., file 05fedf6c-6515-4b74-9852-e6a1d22d22ba 2
Prevalence of Multiple Sclerosis in Patients with Inflammatory Bowel Disease, file 544584f5-bc4c-4efe-980d-9e0629f6cc17 2
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort., file 5a7fdecc-da78-44fd-8fc7-e6bf11edbfec 2
Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification., file 81079215-8860-4b52-8384-459edafcc50d 2
Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment, file e27ce426-f985-2581-e053-d805fe0acbaa 2
Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study., file e27ce427-2b62-2581-e053-d805fe0acbaa 2
HBV cccDNA evaluation in HBV-core antibody (HBcAb)-positive liver transplant donors, file e27ce42a-bc1e-2581-e053-d805fe0acbaa 2
Serum hepatitis B core-related antigen for the prediction of hepatocellular carcinoma development, file e27ce42d-962d-2581-e053-d805fe0acbaa 2
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment., file e27ce432-0d6d-2581-e053-d805fe0acbaa 2
Screening and surveillance of esophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct acting antiviral agents, file e27ce435-0914-2581-e053-d805fe0acbaa 2
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy, file e27ce428-b6bc-2581-e053-d805fe0acbaa 1
DROPLET DIGITAL PCR APPLICATION FOR HEPATITIS DELTA VIREMIA QUANTIFICATION, file e27ce42a-0e70-2581-e053-d805fe0acbaa 1
HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response, file e27ce432-543e-2581-e053-d805fe0acbaa 1
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project., file e34fa3d7-3aea-4db3-885b-fe4aa872f4b0 1
Totale 6.785
Categoria #
all - tutte 9.503
article - articoli 0
book - libri 0
conference - conferenze 445
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.948


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019227 0 0 0 0 0 0 0 0 0 0 119 108
2019/20201.155 93 73 68 125 82 83 83 114 157 118 87 72
2020/20211.137 80 82 89 56 81 102 125 96 85 118 109 114
2021/20221.668 162 120 103 276 205 90 113 71 116 95 214 103
2022/20231.104 43 117 191 137 74 94 116 68 66 111 71 16
2023/2024425 14 30 59 47 48 57 66 54 17 17 16 0
Totale 6.785